In these pathways genes such as CYP2E1, A2M, coagulation factor II (thrombin) (F2), complement factor I (CFI), SERPINC1, integrin, alpha X (complement component 3 receptor 4 subunit) (ITGAX), complement factor B (CFB), C1S, C4BPA, KNG1, transthyretin (prealbumin, amyloidosis type I) (TTR) aldolase B, fructose-bisphosphate (ALDOB), G6PC, MT1B, MT1E, MT1F, MT1G, MT1H, MT1M, MT1X, ADH1A, ADH4 and ACAA2 were predicted as novel prognostic or diagnostic biomarkers and new therapeutic targets in CAD. This evidence concerns the gene MT1X and amyloidosis.